Longevity & biohacking
Navigating the Regulatory, Ethical, and Investment Landscape of Longevity Therapies
When a 68-year-old marathoner in California announced she could shave months off her biological clock with a novel senolytic, headlines screamed "the future is now." Yet beneath the hype lies a maze of FDA rules, policy debates, ethical quandaries, and investor calculus that determines whether such claims become